Form 8-K - Current report:
SEC Accession No. 0001628280-25-037923
Filing Date
2025-08-05
Accepted
2025-08-05 17:05:48
Documents
14
Period of Report
2025-08-05
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K cpix-20250805.htm   iXBRL 8-K 28492
2 EX-99.1 a2025q2-ex991er.htm EX-99.1 230790
6 image_0a.jpg GRAPHIC 24016
  Complete submission text file 0001628280-25-037923.txt   431525

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT cpix-20250805.xsd EX-101.SCH 1894
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT cpix-20250805_lab.xml EX-101.LAB 21885
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT cpix-20250805_pre.xml EX-101.PRE 12611
16 EXTRACTED XBRL INSTANCE DOCUMENT cpix-20250805_htm.xml XML 3015
Mailing Address 2525 WEST END AVENUE SUITE 950 NASHVILLE TN 37203
Business Address 2525 WEST END AVENUE SUITE 950 NASHVILLE, TN 37203 615-255-0068
CUMBERLAND PHARMACEUTICALS INC (Filer) CIK: 0001087294 (see all company filings)

EIN.: 000000000 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-33637 | Film No.: 251186072
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)